Metsera, Inc.
NASDAQ: MTSR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher Whitten Bernard
- Employees
- 93
- Headquarters
- New York City, United States
- IPO year
- 2025
- Market cap
- $7.4B
- Website
- https://metsera.com
Loading MTSR…
Loading profile data…Frequently asked questions about MTSR
What does Metsera, Inc. (MTSR) do?
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both u...
Where does MTSR trade?
Metsera, Inc. (MTSR) trades on the NASDAQ Global Select.
What sector is MTSR in?
Metsera, Inc. (MTSR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Metsera, Inc.?
Christopher Whitten Bernard is the chief executive officer of Metsera, Inc. (MTSR).
Where is Metsera, Inc. headquartered?
Metsera, Inc. is headquartered in United States.
Does MTSR pay a dividend?
Metsera, Inc. (MTSR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MTSR go public?
Metsera, Inc. (MTSR) completed its initial public offering in 2025.